Assembly Biosciences (ASMB)
Develops antiviral and liver-disease candidates through discovery and clinical development.
$25.70
vs last close+0.26 (+1.03%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 92.23% | 18.78M shares | |
|---|---|---|---|
| 97 holders · as of Jun 30, 2026 | |||
| Insiders | 7.13% | 1.45M shares | |
| 10 holders · as of Jun 18, 2026 | |||
| Strategic holders | 6.59% | 1.34M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 105.95% | ||
20.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 105.95%; nothing is left for Other.
13F, as of Jun 30, 2026
97 holders · 18.78M shares · 36 new positions · 69 increased · 19 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 4.98M | 24.44% | +471.7K | Aug 3, 2026 |
| Farallon Capital Management LLC | 1.60M | 7.88% | +377.0K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 1.55M | 7.63% | +888.5K | Aug 14, 2026 |
| Commodore Capital LP | 1.42M | 6.95% | +415.0K | Aug 14, 2026 |
| Ra Capital Management, L.P. | 1.02M | 5.01% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 849.3K | 4.17% | +849.3Knew | Aug 14, 2026 |
| BlackRock, Inc. | 766.8K | 3.77% | +564.1K | Aug 7, 2026 |
| Parkman Healthcare Partners LLC | 721.2K | 3.54% | +310.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 25.10% | 4.98M | 13D | May 27, 2026 |
| Commodore Capital LP | 9.90% | 1.62M | 13G | Aug 15, 2025 |
| RA Capital Management, L.P. | 9.50% | 1.53M | 13G | Aug 18, 2025 |
| Janus Henderson Group PLC | 8.20% | 1.34M | 13G | Dec 8, 2025 |
| Steven Boydincl. Armistice Capital, LLC | 5.58% | 354.0K | Nov 14, 2024 | |
| Paradigm BioCapital Advisors LP | 5.40% | 865.3K | 13G | May 11, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 17, 2026 | Jeanette M. Bjorkquistofficer: PFO and PAO | Sale | 29 | $23.25 | 14,560 |
| Mar 30, 2026 | Nicole S. Whiteofficer: Chief Manufacturing Officer | Sale · 2 lots | 197 | $26.69 | 37,477 |
| Mar 30, 2026 | Jeanette M. Bjorkquistofficer: PFO and PAO | Sale · 2 lots | 328 | $26.69 | 11,089 |
| Aug 8, 2025 | Gilead Sciences, Inc.10 percent owner | Purchase · 3 lots | 4,591,840 | $10.80 | 6,801,311 |
House and Senate disclosures
Not reported.